Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vikair is a multi-component combination drug widely used in Russia and other CIS countries for the treatment of acid-related gastrointestinal disorders, including peptic ulcers and hyperacid gastritis. The formulation consists of bismuth subnitrate, magnesium carbonate, sodium bicarbonate, calamus rhizome powder, and frangula bark powder. Bismuth subnitrate acts as a gastroprotective agent by forming a protein-bismuth complex that coats ulcerated tissue and exhibits antimicrobial activity against *Helicobacter pylori*. The magnesium and sodium salts serve as antacids to neutralize gastric hydrochloric acid, while the herbal components provide mild antispasmodic and laxative properties to counteract the constipating effects of bismuth and magnesium. It is typically administered orally as a tablet.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Vikair.